Counselors in Little Chute, WI Accepting Medicare
6 Counselors found. Showing 1 - 6
 Mrs. Amy Marie Fifield, LPC SASA Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1800 Freedom Rd Ste A, Little Chute, WI 54140 Phone: 920-460-9009 |
Victoria Engels, LPC-IT Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 528 Pine St Ste B, Little Chute, WI 54140 Phone: 920-209-0604 |
Dayna Wolf, SAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 930 Manor Pl, Little Chute, WI 54140 Phone: 920-733-4443 Fax: 920-733-4796 |
Melissa A Chambers, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1800 Freedom Rd, Little Chute, WI 54140 Phone: 920-619-0074 |
Elena De Los Santos Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 528 Pine St Ste B, Little Chute, WI 54140 Phone: 920-209-0604 |
 Timothy Mcmahon, LCSW, SAC-IT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 900 Wisconsin Ct, Little Chute, WI 54140 Phone: 920-205-0088 |
News Archive
DAB2IP gene linked to aggressive prostate cancer
Results from two genome-wide association studies have identified a genetic variant of the DAB2IP gene that is associated with the risk of aggressive prostate cancer.
Colorectal pre-cancer can be detected through stool DNA testing: Mayo Clinic study
Research teams led by Mayo Clinic have demonstrated for the first time that two types of colorectal pre-cancers can be detected through noninvasive stool DNA testing. The two studies being presented demonstrate that stool DNA testing may be useful for detection of premalignant dysplasia in patients with inflammatory bowel disease and of an important type of colorectal pre-cancer called serrated polyps.
Exercise, diet may protect against colorectal cancer
Voluntary exercise and a restricted diet reduced the number and size of pre-cancerous polyps in the intestines of male mice and improved survival, according to a study by a University of Wisconsin-Madison research published in the journal Carcinogenesis.
CryoPatch SG pulmonary human cardiac patch receives FDA clearance for 5-year shelf-life extension
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
› Verified 9 days ago